Analyst Ratings for SAB Biotherapeutics (SABS)
SABS Rating Summary
SABS Price Target Summary
- Highest: $15.00 (Guggenheim)
- Lowest: $6.00 (Craig-Hallum)
- Average: $10.67
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$10.67 (+201.3%)
* Over Last 12-Mos
Rating Score: 9.3 / 10
Percentile Rank: 90%
Rating Score: 9.3 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/24/2026 | Barclays | Eliana Merle | New Coverage | Overweight (N/A) |
13.00 (N/A) |
3.87 (3.54) |
-8.53% | Details |
| 5/22/2026 | Citi | Samantha Semenkow | New Coverage | Buy (N/A) |
11.00 (N/A) |
3.81 (3.54) |
-7.09% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
